Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer.
oleh: Manish A Shah, Zev A Wainberg, Daniel V T Catenacci, Howard S Hochster, James Ford, Pamela Kunz, Fa-Chyi Lee, Howard Kallender, Fabiola Cecchi, Daniel C Rabe, Harold Keer, Anne-Marie Martin, Yuan Liu, Robert Gagnon, Peter Bonate, Li Liu, Tona Gilmer, Donald P Bottaro
| Format: | Article |
|---|---|
| Diterbitkan: | Public Library of Science (PLoS) 2022-01-01 |
Deskripsi
[This corrects the article DOI: 10.1371/journal.pone.0054014.].